It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
From early target ideation to validated assets ready for hit discovery, we help you move faster and reduce risk, bringing clarity and confidence to every decision.
Target Identification and Validation is essential for reducing risk and ensuring therapeutic success.
Our integrated target identification and validation (TI/TV) platform combines AI-driven prioritization, expert insights, and rigorous lab validation to guide targets through robust evaluation and into hit discovery and lead development.
Target Identification
We use a semi-automated, human-in-the-loop approach, powered by AI and machine learning, tailored to your modality and therapeutic focus. Whether you’re pursuing first-in-class or best-in-class, we score and prioritize targets with precision.
Core Components:
• AI‐driven literature and patent analysis using our in-house developed, AI-driven analytics tool, AI4Lit, coupled with Qiagen IPA, Reaxys, and OpenTargets.
• Expert-guided multidisciplinary team target selection: strategic, data-driven and goal-aligned.
• Strategic target selection for commercial success, efficacy, and safety.
• Multimodal applicability: small molecules, peptides, PROTACs, ADCs, macrocycles, and other ‘beyond Rof5’ therapeutic agents.
Our Target ID workflows help narrow down to the most promising target to progress to Sygnature’s Target Validation platform, where we assess the connection between target manipulation and disease efficacy.
Target Validation
This critical phase, typically 2–6 months, confirms whether modulating your target yields therapeutic effects within a safe window, helping prevent late-stage failure.
Our validation solutions include:
• Functional in vitro assays using tool compounds to assess target biology and pharmacology.
• Expression profiling with mRNA/protein distribution analysis, correlated to disease progression.
• Advanced cell-based models, including 3D cultures, co-cultures, and patient-derived iPSC systems.
• Biomarker identification and validation, via transcriptomics (qPCR), protein detection (Luminex), and flow cytometry.
After validation, we ensure a seamless transition into hit identification and discovery-enabled chemistry campaigns.
Integrated TI/TV Workflow
Our five-phase workflow builds from target selection to integrated drug discovery, tailored to your project needs. Direct entry at stages 2, 3, or 4 is supported, and modular design aligns with timelines and budgets. Collaboration is central throughout.
Our methodology can be applied:
• To any therapeutic modality, including: small molecules, peptides, ADCs, PROTACs, molecular glues.
• Across all therapeutic areas, for example: oncology, neurology, cardiovascular, inflammation and metabolic diseases.
• Beyond scoring: evaluating disease relevance, safety, feasibility, and differentiation.
Our Approach
AI-informed
Accelerates prioritization in data-rich landscapes.
Expert-led
Multidisciplinary teams spanning therapeutic areas and modalities.
Lab-validated
Rigorous experimental confirmation before progression.
Deliverable-focused
Clear, actionable rationale and risk analysis.
Continuously evolving
New tools and alliances, including Bullfrog AI integration.
“Our collaboration with Sygnature Discovery has led to successful target identification in our TPD discovery. Their computational science/ bioinformatics/biosciences/ chemistry-integrated approaches allowed us, within a few months, to
unravel the current status of target protein landscape from a certain perspective, and to identify target proteins from our desired angle. We were particularly impressed by Sygnature’s exceptional dedication to success and the thorough
science-based discussions we had with them, which we believe are the key to all successful collaborations.”
Selecting the right protein target is a pivotal step toward drug…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Modalities
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Delivering co-located, multidisciplinary drug discovery programs that combine speed, precision, and scientific rigor to advance candidates with confidence.
